Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?

Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year increase in earnings driven by higher revenues, with the earnings report expected on February 27, 2024, which could significantly influence the stock price depending on the actual results compared to estimates [1][2]. Financial Expectations - The consensus estimate for quarterly earnings is $0.32 per share, reflecting a year-over-year increase of +223.1% [2]. - Expected revenues are projected at $223.08 million, representing a 63.4% increase from the same quarter last year [2]. Estimate Revisions - The consensus EPS estimate has been revised down by 2.47% over the last 30 days, indicating a reassessment by analysts [2]. - Acadia's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -10.08%, suggesting a bearish outlook from analysts [5]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading typically suggests a likely earnings beat, but Acadia's negative Earnings ESP reading complicates predictions for an earnings beat [3][4][6]. - The stock currently holds a Zacks Rank of 3, which does not strongly indicate a likelihood of beating the consensus EPS estimate [5][6]. Historical Performance - In the last reported quarter, Acadia was expected to post a loss of $0.43 per share but reported a loss of $0.40, resulting in a surprise of +6.98% [7]. - Over the past four quarters, Acadia has beaten consensus EPS estimates twice [7]. Conclusion - While Acadia is not positioned as a compelling earnings-beat candidate, investors should consider other factors influencing stock performance ahead of the earnings release [8].